Onyx agrees to $10.4B takeover by Amgen

08/26/2013 | New York Times (tiered subscription model), The

Onyx Pharmaceuticals, which makes three anti-cancer drugs, agreed to a $10.4 billion takeover by Amgen, the world's biggest biotech firm. The $125-per-share price was higher than the $120 Onyx recently rejected but fell short of the $130 that analysts expected.

View Full Article in:

New York Times (tiered subscription model), The

Published in Brief: